Metrics as of 10/14/2026, 05:52 AM (Berlin time), refresh in progress.
Neuphoria Therapeutics Stock
Neuphoria Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Spyridon Papapetropoulos
- Employees
- 1
- Market cap
- $18 M
- IPO
- 16/12/2021
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23,…
Neuphoria Therapeutics stock: price history
1D
-2.9%
1W
-3.8%
1M
-13.4%
6M
-29.2%
YTD
-15.2%
1Y
-79.5%
2Y
+5.1%
5Y
–
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~76% stronger price swings than usual
Ask the agents about Neuphoria Therapeutics
Analyst assessment of Neuphoria Therapeutics
PRICE TARGET LOW
US$7.00
CONSENSUS
US$7.00
MEDIAN
US$7.00
PRICE TARGET HIGH
US$7.00
0
STRONG BUY
1
BUY
1
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 15/05/2026
Neuphoria Therapeutics stock metrics
P/E
-0.45
P/B
0.72
EV/EBITDA
0.16
RETURN ON EQUITY
-19.9%
NET MARGIN
-417.7%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.5%
FLOAT SHARES
4,186,689
AVG. DAILY VOLUME (30D)
16,054
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Neuphoria Therapeutics stock
What does Neuphoria Therapeutics do?
Neuphoria Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Spyridon Papapetropoulos, the company employs around 1 people.
The IPO was on 16/12/2021; the stock trades on NASDAQ under the ticker NEUP.
What do analysts say about Neuphoria Therapeutics stock?
2 analysts rate the stock, the consensus is Buy (as of 15/05/2026).
The average price target is US$7.00, ranging from US$7.00 to US$7.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
When does Neuphoria Therapeutics report next?
Around past earnings, price swings were roughly 76% stronger than usual.
Does Neuphoria Therapeutics pay a dividend?
No, Neuphoria Therapeutics currently does not pay a dividend.
Which stocks are comparable to Neuphoria Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Neuphoria Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Neuphoria Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.